GlassScriptPhysician profile
Gregg Colle
NPI 1720195993
$7,551.20
in general payments reported to CMS, 2019-2025
23 companies · $450 in 2025
The $450 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,353 · 2020: $1,274 · 2021: $1,020 · 2022: $1,108 · 2023: $1,199 · 2024: $1,147 · 2025: $450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,795.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,348.54 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $1,184.52 | 2019-2025 | Tremfya, Stelara, Simponi |
| Ucb, INC. | $1,041.93 | 2019-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $765.07 | 2019-2024 | |
| Lilly USA, LLC | $734.42 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Amgen INC. | $601.75 | 2019-2025 | Otezla |
| Regeneron Healthcare Solutions, INC. | $393.10 | 2019-2022 | |
| Genzyme Corporation | $376.10 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $340.96 | 2019-2023 | Ilumya |
| E.R. Squibb & Sons, L.L.C. | $321.67 | 2022-2025 | Sotyktu |
| Celgene Corporation | $79.39 | 2019 | |
| Pfizer INC. | $78.04 | 2019-2022 | |
| Galderma Laboratories, L.P. | $76.78 | 2024-2025 | Nemluvio |
| Mylan Institutional INC. | $35.99 | 2023 | Hulio |
| Leo Pharma INC. | $33.72 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.33 | 2022-2023 | Spevigo |
| Journey Medical Corporation | $23.30 | 2022 | |
| Fresenius Kabi USA, LLC | $18.99 | 2023 | |
| Arcutis Biotherapeutics, INC. | $16.09 | 2023 | |
| Nabriva Therapeutics, Plc | $15.99 | 2022 | |
| Genentech USA, INC. | $13.21 | 2020 | |
| Merck Sharp & Dohme LLC | $11.47 | 2019 | |
| Prugen, INC. Pharmaceuticals | $6.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregg Colle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.